Espada Dermatology, a wholly owned subsidiary of Mission Pharmacal Company, has announced its recent purchase of the GlyDerm line of skincare products from Lautus Pharmaceuticals. The GlyDerm line of products delivers gentle yet effective glycolic acid to the skin via a proprietary esterification process, which allows for a time-released delivery to reduce signs of aging and photodamage.
To support Espada’s acquisition, Trey Schutz has joined the company as vice president and general manager of Mission Dermatology. With more than 20 years of progressive experience focusing on new product development, Schutz will oversee a product portfolio of dermatology products that have both a prescription and consumer focus.
“This acquisition demonstrates Mission’s focus and commitment to dermatology and skin health,” said Terry Herring, president of commercial operations at Mission. “We look forward to partnering with healthcare providers in the growth and expansion of aesthetic dermatology and improving the care and treatment of patients. We are excited to offer GlyDerm, a product with a proven track record in esthetic dermatology and skin health.”
